Today: November 27, 2015, 12:19 am

Global haemorrhages drugs market is forecast to attain revenues of S$13.5Bn in 2017
Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024 - a new market research report on 2014-04-03 00:27:01
The global drugs market for preventing haemorrhages will generate $13.5bn in 2017. It is anticipated that the large medical companies and biopharma specialists will perform strongly over the next few years within the global bleeding disorders market.Between 2012 and 2018, revenue generated by sales of Helixate will increase at a CAGR of 0.16%. Between 2018 and 2024, revenue will decrease at a CAGR of -1.5%. In 2024, sales of the drug will generate $463m, accounting for 2.67% of the total market.Nplate represents the leading product for thrombocytopenia in 2012. Nplate is marketed by Amgen. It was approved by the FDA in August 2008 and by the EMA in February 2009 for the treatment of thrombocytopenia in adults with idiopathic thrombocytopenic purpura, an autoimmune disease. It is a fusion protein analogue of thrombopoietin, a naturally occurring hormone which regulates platelet count. Nplate works by raising and sustaining the blood platelet count using the same mechanism of action as this hormone. Upon its launch, it represented a novel therapeutic approach to thrombocytopenia in this patient population.In 2012, sales of Nplate generated $368m. The product has seen strong annual growth in recent years. Driving this strong revenue generation is the chronic nature of the disease, which requires long term treatment, generating repeat sales. Additionally, Amgen is licensed to market Nplate in the US, all of Europe, Canada, Australia, New Zealand, Mexico, all Central and South American countries and certain countries in Africa, Asia and the Middle East meaning the drug is available to a large patient population. After approval, Nplate was subject to restricted distribution as a result of safety concerns arising from the limited experience with the drug. However, these Risk Evaluation and Modification Strategies (REMS) were modified in December 2011; prescribers, healthcare institutions, pharmacies and patients no longer have to enroll in REMS programmes in order to prescribe, dispense or take these drugs. This modification has resulted in an expanding market for Nplate.Amgen is conducting clinical trials with Nplate in the treatment of thrombocytopenia caused by hepatitis C, multiple myeloma and other cancers (chemotherapy-induced). Indication expansions will also result in an expanding market for Nplate. As a result of these factors, revenue generated by Nplate will see strong growth until 2016. Between 2012 and 2018, revenue generated by Nplate will expand at a CAGR of 7.65%. However, Nplate competes directly with GlaxoSmithKline´s Promacta and from 2016 onwards, the annual rate of growth in revenue will begin to decline as a result of market saturation.Revenue generated by Nplate will peak in 2020 at $590m, accounting for 3.76% of the total bleeding disorders market. From 2021 onwards competition in the market will result in negative annual growth. Between 2018 and 2024, revenue will decrease at a CAGR of -1.36%. In 2024, sales of Nplate will generate $527m, accounting for 3.05% of the total market.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 662 Words
Related Articles
More From Finance
USGFX Anticipates A Rise In Forex Trading [..]
The Shanghai Composite Index has been volatile and at one stage dropped more than 30% from its June 12 peak, [..]
Credit-Yogi Recommends Reputable Debt Solution Companies To [..]
Many people who have poor credit don’t know what to do about it. They realize that their bad credit prevents [..]
Credit-Yogi Reveals Special Considerations for Military Members [..]
No one wants to have their vehicle taken back by their banks. It’s a source of stress for the individual [..]
Credit-Yogi Teaches Consumers How To Use HAMP [..]
Be Prepared to Utilize HAMP Lenders do not like to help borrowers prevent foreclosure by accessing the Obama loan modification [..]
Credit-Yogi Informs Military Members Facing Auto Repossession [..]
No one wants to have their vehicle taken back by their banks. It’s a source of stress for the individual [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.